SYRE Q4 2017 Earnings — Spyre Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SYRESpyre Therapeutics, Inc.

$3B

Q4 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M+18.8% YoY

Gross Profit

$00.0% margin

Operating Income

-$7M-447.1% margin

Net Income

-$6M-437.4% margin

EPS (Diluted)

$-10.19

QoQ Revenue Growth

+17.5%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$698,000

Balance Sheet

Total Assets

$56M

Total Liabilities

$6M

Stockholders' Equity

$50M

Cash & Equivalents

$13M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$1M	+18.8%
Gross Profit	$0	$0	—
Operating Income	-$7M	-$6M	-19.5%
Net Income	-$6M	-$5M	-18.2%